ProteinQure announced first patient dosed in Phase I clinical trial of PQ203 in advanced metastatic cancer

ProteinQure, a Toronto-based biotech company pioneering computational peptide drug discovery, recently announced the successful dosing of the first patient in its Phase I clinical trial evaluating PQ203 – a novel, rationally designed peptide therapeutic for advanced metastatic solid tumors. The trial is being started at Princess Margaret Cancer Centre in Toronto, one of the world’s top five cancer research centres.

ProteinQure is an OBIO® member, an alumnus of our BDSP™, CAAP®, HealthMINT® programs and Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, and presented at the OBIO® Investment Summit.